Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia 2011-11, Vol.17 (6), p.854-859
• Main Authors: MARTINOWITZ, U., BJERRE, J., BRAND, B., KLAMROTH, R., MISGAV, M., MORFINI, M., SANTAGOSTINO, E., TIEDE, A., VIUFF, D.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; bioequivalence; Child; Coagulants - pharmacokinetics; Factor VIII - pharmacokinetics; first human dose; haemophilia A; Hemophilia A - drug therapy; Hemophilia A - metabolism; Humans; Male; Middle Aged; open label; pharmacokinetics; Recombinant Proteins - pharmacokinetics; rFVIII; Therapeutic Equivalency; Young Adult
• ISSN: 1351-8216; 1365-2516
• DOI: 10.1111/j.1365-2516.2011.02495.x

Recombinant coagulation factor VIII (rFVIII) concentrates provide a safe and efficacious replacement therapy for treatment and prevention of bleeding in patients with severe haemophilia A. The aim of this study was to compare the pharmacokinetic (PK) and safety profiles of two serum‐free rFVIII products: N8, a new rFVIII manufactured by Novo Nordisk and Advate®, a marketed product. Patients with severe haemophilia A with >150 exposure days to FVIII, without current or past inhibitors, were enrolled in an open‐label, first human dose (FHD), multicentre trial. Twenty‐three patients first received a single dose of 50 IU kg−1 body weight Advate® followed by 50 IU kg−1 body weight N8 at the next visit. A 4‐day washout period was required prior to each dosing. Blood samples for PK and safety analyses were drawn prior to dosing and at intervals up until 48 h postdosing. The PK parameters were based on FVIII clotting activity (FVIII:C) measurements. Occurrence of adverse events was closely monitored. The mean profiles of FVIII:C and all primary and secondary parameters for Advate® and N8 were comparable. The 90% CI for the treatment ratio (Advate®/N8) for all primary endpoints (incremental recovery, t1/2, AUC and Cl), and the secondary endpoints (AUClast and Cmax) were within the bioequivalence interval of 0.8–1.25. There were no safety concerns in the study and no reports of inhibitor formation in the 72‐h period following exposure to a single N8 dose. In conclusion, N8 is bioequivalent to Advate®. Furthermore, N8 is well tolerated in the FHD trial.